All timeline stories.
The FDA authorization enables Hemerion to commence a Phase 1/2 clinical study at University of Pittsburgh Medical Center by Q4 2023 to evaluate the upgraded Pentalafen® / Heliance® platform. Read the press release
Hemerion is one of the 2020 laureates of the Réseau Entreprendre®, the first international private network of business leaders, with 126 locations worldwide, grouped in 65 associations.
Hemerion is one of the winners designated by Hodéfi, an association that finances and supports innovative companies in the Hauts-de-France region, and has received one of its first grants.
Hemerion wins the therapeutic innovation prize awarded by HDFID, an economic development and innovation agency supported by the Hauts de France Region.
SATT Nord, a specialist in technology transfer from public research laboratories, grants Hemerion Therapeutics an exclusive license to exploit the anti-cancer technology co-developed by INSERM, the University of Lille and the Lille University Hospital.
Hemerion has set new milestones for its international development during a 5-day mission in Boston. Read more
One year after the first round of funding, Hemerion’s new €3.55 million financing will accelerate the implementation of international clinical trials for the treatment of glioblastoma. Read more – Press release
Hemerion and Mount Sinai Health System (NYC) are collaborating to launch an ambitious clinical trial in 2022. This project has won the “Best Collaboration in the MedTech and Digital Health” award of the Galien Medstartup Prize: an international recognition that perfectly kickstarts the Hemerion development in the USA. Read more – Press release
Authorization granted for a phase 2 clinical trial that aims to evaluate the technology developed by Hemerion. This study is sponsored by the Lille University Hopital (France).
For its preliminary funding round, Hemerion gathers 1.5M€ in dilutive and non-dilutive funding to further validate its therapeutic approach.